Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer
|
|
- Gerard Conley
- 5 years ago
- Views:
Transcription
1 Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer RadioGraphics 2018; 38: Pritesh Patel, MD Melvy S. Mathew, MD Igor Trilisky, MD Aytekin Oto, MD, MBA Jeffrey S. Klein, MD Hi. I m Jeff Klein, Editor of Radio- Graphics and today I m pleased to have with us Dr. Pritesh Patel from the University of Chicago Medical Center, Department of Radiology who is the first author of one of our featured papers in the current March 2018 issue of Radio- Graphics. His paper is entitled Multiparametric MR Imaging of Prostate Cancer Following Treatment. Dr. Patel welcome. Pritesh Patel, MD Well thank you very much Dr. Klein. J.S.K. So Pritesh your paper in the current issue deals with a very important topic and it begins with an introduction that discusses the expanding treatment options that we have available for prostate cancer, in particular some of the non-surgical local therapies that are now being employed in selected patients. Can you briefly review for us the spectrum of treatment options that are currently available and touch on why it s important for radiologists to be familiar with the imaging findings, not only after standard surgical and radiation treatments, but also after receiving some of these more novel local therapies for prostate cancer? P.P. Sure, before I begin just on behalf of Dr. Aytekin Oto we d like to thank you again for this opportunity to meet you here at RSNA. J.S.K. Thank you. P.P. So prostate cancer is a little different than most other cancers in that there s a wide spectrum of treatment available. On one end, you have no intervention with active surveillance, or minimal intervention with hormonal therapy; and on the other end you have more aggressive interventions such as surgery, most commonly radical prostatectomy and radiation therapy. In between we have these emerging focal therapies. The focal therapies that are being researched right now include laser ablation, cryoablation, electroporation, photodynamic therapy, and ultrasonic ablation. Now these are increasing in prevalence for example we re part of a multi-center trial dealing with ultrasonic ablation. So given that and the wide variety of treatments available, we really need to know as much about the tumor as we can, and MRI plays a critical role in this. But beyond just knowing how to characterize or diagnose a tumor, each one of these modalities or treatment options can use MRI differently. For example with active surveillance we can use MRI to perhaps prevent frequent biopsies or detect recurrence after a positive PSA but negative biopsies, but more importantly with focal therapies after they are performed, they re really the only way we know to diagnose recurrence because PSA becomes an unreliable biomarker because there s residual prostatic tissue. Therefore, the radiologist really needs to know not only how to diagnose prostate cancer on MRI, but be aware of its role in these treatment options. J.S.K. Absolutely. Well thank you for that. So in your paper after you review the typical MR appearance of prostate cancer, you continue to describe the passive and active approaches to treatment which with the passive approach essentially being as you described active surveillance which so is a little bit of a contradiction in terms, but can you review for us the concept of active surveillance in prostate cancer management? In particular which patients would active surveillance be appropriate for? P.P. Sure yeah so active surveillance at its core is just when a patient has known prostate cancer, but is not no intervention is performed. So the patient is placed instead in a surveillance program. So typically patients who are in active surveillance are of low risk prostate cancer, but what does that exactly mean? What does low risk mean? Well that depends on your institution. So there s a bunch of risk classification guidelines that are out there. The most commonly used one by the European Urologic Association and the American Urologic Association is a three-tiered system of low, intermediate, and high-risk prostate cancer. So a low risk patient for active surveillance is one that has a Gleason score of less than or equal to 6, a PSA of less than or equal to 10, and stage T1C or T2A disease. Now your institution may also employ further criteria such as the Epstein Inclusion Criteria which is the most commonly included one. And that adds tumor volume which is based on the percentage of tumor seen within cores and the number of positive cores that have tumor within them. Unfortunately active surveillance is often misclassified. So 20 to 30 percent are not being put into active surveillance which leads to unnecessary complications down the line such as erectile dysfunction or urinary incontinence. J.S.K. Well that s great so after talking about the active and passive surveillance you begin then to delve into the surgical and radiation treatment options which have sort of been the standard treatment options for people with localized prostate cancer for some time. Let s discuss surgery and then we could look at Figures 3 and 4 which showed both the normal postoperative appearance on MR and Figure 4 which shows an example I think of MR detection of local recurrence of disease. P.P. Sure. Yeah so Figure 3 shows the characteristic find-
2 ings of postsurgical changes after radical prostatectomy. The bladder and the levator sling have descended into the space formerly occupied by the prostate and there s a new vesicle urethral anastomosis. The vesicle urethral anastomosis can have variable signal depending on the fibrosis that s present. Other things to look out for that aren t shown in this image are postsurgical collections commonly abscess, hematoma, lymphocele, or urinoma. Figure 4 shows classic recurrence at the vesicle urethral anastomosis which is similar to the primary tumor low T2, low ADC, early contrast enhancement. This is the most common location, but you should also be checking the antral lateral surgical margin, the space between the bladder and the rectum and in seminal vesicles if they happen to be retained. A couple pitfalls to watch out for are fibrosis and residual prostatic tissue. J.S.K. Right. Well thanks for that. So in detailing the imaging of patients who have received treatment with radiation, you describe a typical post-treatment MR appearance of a decrease in gland size and obviously uniform decrease in you know T2 signal intensity which makes the detection of recurrent disease fairly difficult. Although as you state it s the more common site of disease recurrence is in that area, and this is in distinction to postsurgical recurrence which is most common at the vesicle urethra junction as you have shown us in Figure 4. Your paper then proceeds to discuss the increasing number of local therapies as you mentioned earlier including photodynamic therapy, high-intensity focused ultrasound HIFU, cyroablation, laser treatment and electroporation. Let s take a look at cyroablation which I think it would be good to just review quickly which patients are candidates for cyroablative therapy and then we ll look at Figures 9 and 10 which show two different patients who received cryotherapy and we ll review their findings. P.P. Cyroablation along with the other focal therapies are still developing their role in the treatment paradigm for prostate cancer. However most papers suggest the cyroablation can be used in low-, intermediate-, or high-risk prostate cancer. And sometimes it can be used in salvage therapy after a recurrence after radiation therapy. The cyroablation is when you insert needles into the prosthetic tissue under trans-rectal ultrasound guidance and infuse low temperature gases eventually leading to necrosis of the tissue. Unfortunately there s no consensus as to how much tissue to ablate, so most people end up doing a hemi-ablation trying to spare the neurovascular bundle. So Figure 9 shows your normal appearance after cryotherapy. The first image is an axial T2 image which is showing the very low signal in the left prostate gland and the key here is it also extends through the surrounding pelvic structures. Some of the therapies we talk about later may not do that. Also the part B of the image shows post contrast imaging that has no enhancement in the ablated area compared to the remaining prostate gland and at level C there s a little bit of asymmetry in both peripheral zones and a small amount of fluid in between the peripheral zone and transitional zone. And Figure 10 shows a classic recurrence after cryotherapy. So on one side, on the left side, you have normal postsurgical changes after cryotherapy and you see the recurrence on the right anterior peripheral zone which is low in T2, low in ADC, and not shown but has contrast enhancement here. J.S.K. Alright, great, thank you for that. So let s just move on to talk about laser ablation as a potential therapy. Can you describe how this procedure is performed and why it might be a preferred therapy as compared to the other local treatment options for patients with prostate cancer? P.P. Yeah absolutely. So laser ablation is when you direct a laser beam under MRI guidance to thermally ablate prostatic tissue. So the advantage of focal laser therapy over some of these other ablative measures is that it can be focused and directed since you re using MRI guidance so you can localize it better as well. On top of that, you can use real time temperature monitoring with MR thermometry to really make sure that you re getting an adequate temperature to really ablate those tissues. It s important to note that you want to try to ablate a little bit more than the tumor itself because certain studies have shown that MR may underestimate tumor volume and so that s a good thing to do. J.S.K. And let s look at Figure 11 which I think illustrates a patient who has received laser ablative therapy for their prostate cancer. P.P. Right so Figure 11 shows normal appearance after somebody who has laser ablation like you mentioned. The first image is a pre-treatment image that shows you the biopsy proven cancer in the right peripheral zone and immediately after ablation on the post-contrast image there s a large unenhanced ablation zone which has peripheral rim enhancement which is a characteristic finding of these ablation zones. Three months later you get to see the long-term effects of this as there s architectural distortion, fibrosis, and shift of the volume towards the right particularly the urethra. J.S.K. Great. Thank you for that. So finally, you make an important point in the paper that the role, using the role of dynamic contrast enhanced MR and also in diffusion weighted imaging in particular in the detections of disease recurrence in patients who have undergone treatment. And I think Figure 12 illustrates this nicely. Can we take a look at this particular case which I think demonstrates recurrent disease in a patient who had undergone laser ablative therapy for their prostate cancer? P.P. Yeah you re absolutely right. You know when we have these therapies they tend to mess up our normal sensitivity of T2 weighted sequences given the post-treatment changes such as fibrosis or atrophy and loss of differentiation between the peripheral zone and traditional zone so it s really key to use DCE MR and DWI to really pick out these lesions. This figure is a good example of that. It shows recurrence after focal ablation, focal laser ablation. And what it shows is a really low intensity ablation zone in the left paracentral peripheral zone and there s a new mildly lobulated low T2 biopsy prov-
3 en recurrence in the posterior left peripheral zone. The subsequent DCE image shows focus of contrast enhancement which corresponds to that low T2 signal and also there is incidentally seen in the right peripheral zone another focus of cancer. J.S.K. Great. Well Dr. Patel I want to thank you for taking the time to talk with us today about your paper which is on the MR imaging of patients who have undergone prostate cancer treatment which again appears in the current March 2018 issue of RadioGraphics. P.P. I really appreciate the opportunity. Thank you so much. J.S.K. Thank you.
4
5
TOOKAD (padeliporfin) Patient Information Guide
TOOKAD (padeliporfin) Patient Information Guide TOOKAD is used to treat low-risk localized prostate cancer This medicine is subject to additional monitoring. This will allow quick identification of new
More information11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.
Multi-parametric MRI of Prostate Diagnosis and Treatment Planning Temel Tirkes, M.D. Associate Professor of Radiology Director, Genitourinary Radiology Indiana University School of Medicine Department
More informationProstate MRI. Overview. Introduction 2/20/2015. Prostate cancer is most frequently diagnosed noncutaneous cancer in males (25%)
Prostate MRI John Bell, MD Introduction Prostate Cancer Screening Staging Anatomy Prostate MRI overview Functional MRI Multiparametric Approach Indications Example Cases Overview Introduction Prostate
More informationPROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging
PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role
More informationProstate Cancer. David Wilkinson MD Gulfshore Urology
Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)
More informationDepartment of Urology, Cochin hospital Paris Descartes University
Technical advances in the treatment of localized prostate cancer Pr Michaël Peyromaure Department of Urology, Cochin hospital Paris Descartes University Introduction Curative treatments of localized prostate
More informationUtility of Prostate MRI. John R. Leyendecker, MD
Utility of Prostate MRI John R. Leyendecker, MD Professor of Radiology and Urology Executive Vice Chair of Clinical Operations Section Head, Abdominal Imaging Wake Forest University School of Medicine;
More informationf) DATTOLI CANCER CENTER
f) DATTOLI CANCER CENTER Why Focal Therapies Won't Work Michael Dattoli, MD New prostate cancer treatment theories, therapies and approaches seem to surface every month or so these days. It is a challenge
More informationWhat Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).
What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,
More informationPROSTATE CANCER CONTENT CREATED BY. Learn more at
PROSTATE CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Ask your doctor about screening and treatment options. WHAT IS PROSTATE CANCER? 4 WATCHFUL
More informationProstate Cancer MRI. Accurate Diagnosis and Treatment. PSA to Prostate MRI. for patients and curious doctors
6 Prostate Cancer MRI Accurate Diagnosis and Treatment PSA to Prostate MRI for patients and curious doctors Samuel Aronson, M.D. Vincent Pelsser, M.D. Franck Bladou, M.D. Armen Aprikian, M.D. & Marc Emberton,
More informationProstate Cancer Treatment Experts
Prostate Cancer Treatment Experts Category Offering HIFU A Cutting-Edge, Non-Invasive Treatment with Low Risk of Side Effects While prostate cancer is a fairly common disease among men in the US, with
More informationNICE BULLETIN Diagnosis & treatment of prostate cancer
Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In
More informationClinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease Jeffrey A. Cadeddu, MD Professor, Department of Urology UT Southwestern Medical Center Vice-Chair, AUA/ASTRO/SUO
More informationAllinaHealthSystems 1
2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology
More informationFocal Therapy for Localized Prostate Cancer Future directions
Smilow Comprehensive Prostate Cancer Center Focal Therapy for Localized Prostate Cancer Future directions Samir S. Taneja, MD The James M. and Janet Riha Neissa Professor of Urologic Oncology Professor
More informationProstate Cancer Case Study 1. Medical Student Case-Based Learning
Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You
More informationQUESTIONS TO ASK A UROLOGIST
QUESTIONS TO ASK A UROLOGIST For the patient: You should review these questions and determine if the answers would satisfy a better understanding of what to expect and ease your concerns. If there are
More informationProstatic Cryosurgery and Robotic Prostatectomy
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/prostatic-cryosurgery-androbotic-prostatectomy/4013/
More informationProblems: TRUS Bx. Clinical questions in PCa. Objectives. Jelle Barentsz. Prostate MR Center of Excellence.
Multi-parametric MR imaging in Problems: TRUS Bx Low Risk Prostate Cancer Important cancers are missed Jelle Barentsz Clinically insignificant cancers are identified by Prostate MR Center of Excellence
More informationMRI Based treatment planning for with focus on prostate cancer. Xinglei Shen, MD Department of Radiation Oncology KUMC
MRI Based treatment planning for with focus on prostate cancer Xinglei Shen, MD Department of Radiation Oncology KUMC Overview How magnetic resonance imaging works (very simple version) Indications for
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationIf you have aggressive cancer, you would want treatment in time for a cure.
Prostate cancer: PSA screening, biopsy, new technologies The treatment/cure should never be worse than the disease. If you have aggressive cancer, you would want treatment in time for a cure. What is PSA?
More informationRadical prostate surgery?
Decipher enables personalized and actionable treatment after surgery Radical prostate surgery? The Decipher Prostate Cancer Classifier can help you and your doctor decide on important next steps in your
More informationTreating localised prostate cancer using freezing (cryotherapy) needles in a targeted area of the prostate
Issue date April 2012 Understanding NICE guidance Information for people who use NHS services NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical
More informationS Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet
S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet Why HIFU? Efficacy demonstrated Real time control of the target Early control of the necrosis area is possible with MRI or TRUS using contrast
More informationUROLOGY. Innovation in Bladder Cancer Treatment CHICAGO ACCESS. How to Refer a Patient. Clinical Trials at UChicago Medicine: Ask Us More Questions!
Clinical Trials at UChicago Medicine: UNIVERSITY OF MEDICINE Department of Surgery 5841 South Maryland Avenue, MC 3026 Chicago, IL 60637 FALL 2015 REFERRING PHYSICIAN NE WSLE T TER FROM THE UNIVERSIT Y
More informationImaging of prostate cancer local recurrences : why and how?
Imaging of prostate cancer local recurrences : why and how? Olivier Rouvière Department of Urinary and Vascular Imaging Hospices Civils de Lyon Lyon - France 1. Preliminary Remarks Preliminary Remarks
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationEffective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18
PROVIDENCE HEALTH PLANS MEDICAL (HIFU) (All Lines of Business Except Medicare) Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18 11/1/18 Medical Officer
More informationPatient Information. Prostate Tissue Ablation. High Intensity Focused Ultrasound for
High Intensity Focused Ultrasound for Prostate Tissue Ablation Patient Information CAUTION: Federal law restricts this device to sell by or on the order of a physician CONTENT Introduction... 3 The prostate...
More informationTechnology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546
Padeliporfin for untreated localised prostate cancer Technology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546 NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More information1. Benign Prostate Hyperplexia (BPH) 2. Prostate Cancer (PCa)
Objectives: Our first segment focused in the anatomy and functions of the prostate gland, to get a clear understanding of the male Genito-Urinary System. Now, we will explore two of the main problems associated
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationYour Guide to Prostate Cancer
Your Guide to Prostate Cancer If you face a diagnosis of prostate cancer, what s next? We can help. A prostate cancer diagnosis can be overwhelming. The good news is that while prostate cancer can be serious,
More informationThe Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon
Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationI have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.
Prostate t Cancer MR Report Disclosure Information Vikas Kundra, M.D, Ph.D. I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a g product
More informationLocalized Prostate Cancer and Its Treatment- A Patient Guide
Your Health Matters Localized Prostate Cancer and Its Treatment- A Patient Guide Department of Urology UCSF Helen Diller Family Comprehensive Cancer Center University of California. San Francisco 550 16th
More informationThe state of prostate cancer management and therapies, courtesy of Sperling Prostate Center in Florida
The state of prostate cancer management and therapies, courtesy of Sperling Prostate Center in Florida 1 QUALITY OF LIFE WITH AN AGING PROSTATE: THE PROTOCOL Dan Sperling, MD, DABR Medical Director The
More informationProstate MRI: Not So Difficult. Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX
Prostate MRI: Not So Difficult Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX What is the biggest barrier to your practice incorporating prostate MRI? 1) I don t know how to read the cases 2) I don
More informationProstate Cancer. What is prostate cancer?
Scan for mobile link. Prostate Cancer Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam, prostate-specific
More informationMR-US Fusion. Image-guided prostate biopsy. Richard E Fan Department of Urology Stanford University
MR-US Fusion Image-guided prostate biopsy Richard E Fan Department of Urology Stanford University Who am I? An instructor in the Department of Urology Quick plug for MED 275B Intro to Biodesign for Undergraduates
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationProstate Cancer DFP Case of the Week
Prostate Cancer DFP Case of the Week Antonio C. Westphalen, MD PhD Clinical Prostate MR Imaging Program, Director Associate Professor of Radiology and Urology University of California, San Francisco Case
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More informationBLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER
BLADDER PROSTATE PENIS TESTICLES THE PROSTATE IS A SMALL, WALNUT-SIZED GLAND THAT IS PART OF THE MALE REPRODUCTIVE SYSTEM. IT RESTS BELOW THE BLADDER, IN FRONT OF THE RECTUM AND SURROUNDS PART OF THE URETHRA.
More informationProstate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018
Prostate cancer staging and datasets: The Nitty-Gritty What determines our pathological reports? Dan Berney Maastricht 2018 Biopsy reporting. How not to do it. The TNM 8 th edition. Changes good and bad
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationFOCAL THERAPY OF PROSTATE CANCER : WHERE ARE WE? MICHAEL MARBERGER PROFESSOR AND CHAIRMAN DEPARTMENT OF UROLOGY MEDICAL UNIVERSITY OF VIENNA
FOCAL THERAPY OF PROSTATE CANCER : WHERE ARE WE? MICHAEL MARBERGER PROFESSOR AND CHAIRMAN DEPARTMENT OF UROLOGY MEDICAL UNIVERSITY OF VIENNA pt2a GL.SC. 6 (3+3) IS TREATMENT OF ENTIRE GLAND NEEDED? MR
More informationChapter 18: Glossary
Chapter 18: Glossary Sutter Health Cancer Service Line: Prostate Committee Advanced cancer: When the cancer has spread to other parts of the body (including lymph nodes, bones, or other organs) and is
More informationProstate MRI for local staging and surgical planning in prostate cancer
Prostate MRI for local staging and surgical planning in prostate cancer 15th Annual Floyd A. Fried Advances in Urology Symposium June 23, 2017 Ray Tan, MD, MSHPM Assistant Professor Disclosures None Objectives
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationProstate Cancer Awareness - Prevention, Symptoms and. Treatment
Quality Assurance Lunch and Learn Sessions: Prostate Cancer Awareness - Prevention, Symptoms and What s wrong with my prostate? Treatment??? Sponsored by the Chief Engineer s Team and Quality Assurance
More informationPCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 77 September October 2012 CONTENT Page The Prostate 1 Health Index Active Surveillance 2 A
More informationIntroduction. Growths in the prostate can be benign (not cancer) or malignant (cancer).
This information was taken from urologyhealth.org. Feel free to explore their website to learn more. Another trusted website with good information is the national comprehensive cancer network (nccn.org).
More informationStephen McManus, MD David Levi, MD
Stephen McManus, MD David Levi, MD Prostate MRI Indications INITIAL DETECTION, STAGING, RECURRENT TUMOR LOCALIZATION, RADIATION THERAPY PLANNING INITIAL DETECTION Clinically suspected prostate cancer before
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More informationQuality of Life with an Aging Prostate: The Sperling Prostate Center Protocol. Dan Sperling, MD, DABR The Sperling Prostate Center Delray Beach, FL
Quality of Life with an Aging Prostate: The Sperling Prostate Center Protocol Dan Sperling, MD, DABR The Sperling Prostate Center Delray Beach, FL As men age, physiological changes affect QOL Testosterone
More informationProstate Cancer. What is the prostate?
Prostate Cancer Prostate cancer is the third-leading cause of cancer deaths among men in the United States. Yet, when detected in its early stages, prostate cancer can be effectively treated and cured.
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationInformation for Patients. Prostate cancer. English
Information for Patients Prostate cancer English Table of contents What is prostate cancer?... 3 The role of hormones in prostate cancer cell growth... 3 Stages of the disease... 3 Risk factors for prostate
More informationProstate Cancer. What is prostate cancer?
Scan for mobile link. Prostate Cancer Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum, below the bladder and above the base of the penis. Your doctor may perform
More informationADVICE TO PATIENTS REQUESTING PSA MEASUREMENT FREQUENTLY-ASKED QUESTIONS
The British Association of Urological Surgeons 35-43 Lincoln s Inn Fields London WC2A 3PE Phone: Fax: Website: E-mail: +44 (0)20 7869 6950 +44 (0)20 7404 5048 www.baus.org.uk admin@baus.org.uk ADVICE TO
More informationProstate Focal Therapy: What s on the Horizon? Thomas J Polascik, MD FACS
Prostate Focal Therapy: What s on the Horizon? Thomas J Polascik, MD FACS Current State of Prostate Focal Therapy Patient Selection Focal Ablation Technology and Technique Follow-up/ Surveillance after
More informationHigh Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November D. Maruzzi - L. Ruggera
High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November 2014 D. Maruzzi - L. Ruggera HIFU development Second prototype 1995-2000 Integrated Imaging 2006-2010 1993
More informationBiodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer Radiotherapy
More informationProstatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London
Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of
More informationda Vinci Prostatectomy
da Vinci Prostatectomy Justin T. Lee MD Director of Robotic Surgery Urology Associates of North Texas (UANT) USMD Prostate Cancer Center (www.usmdpcc.com) Prostate Cancer Facts Prostate cancer Leading
More informationMr Jeremy Grummet, Urological Surgeon MBBS, MS, FRACS Foundation 49 Men s Health Symposium August 2015
www.drjeremygrummet.com.au www.aua.com.au Mr Jeremy Grummet, Urological Surgeon MBBS, MS, FRACS Foundation 49 Men s Health Symposium August 2015 The dilemma Most men die with prostate cancer rather than
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationProstate cancer. A guide for men who ve just been diagnosed
Prostate cancer A guide for men who ve just been diagnosed 2 Prostate cancer A guide for men who ve just been diagnosed About this booklet This booklet is for men who ve recently been diagnosed with prostate
More informationBiodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer Radiotherapy
More informationIrreversible Electroporation for the Treatment of Recurrent Prostate Cancer
Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationJournée industrielle PRIMES, 12 juin Nicolas Guillen, EDAP TMS France
Multi modality imaging for prostate cancer targeting and treatment Journée industrielle PRIMES, 12 juin 2014 Nicolas Guillen, EDAP TMS France Focal One device Focal One is the first device dedicated to
More informationADVICE TO PATIENTS REQUESTING PSA MEASUREMENT
Frequently-Asked Questions What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication of prostate cancer, is available to you if you want
More informationMen s Health Topics. Jerome Baca, MS, PA-C. Albuquerque Urology Associates January 6 th, 2018
Men s Health Topics Jerome Baca, MS, PA-C Albuquerque Urology Associates January 6 th, 2018 1 ns 2 Prostate Cancer (pca) Most common type of cancer in men 45-75yo > 95% is adenocarcinoma: CA arising from
More informationSalvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationRole of surgery. Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam
Role of surgery Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Surgery and alternative treatments Radical prostatectomy Open Laparoscopic Robot-assisted Temperature
More informationTreating Prostate Cancer
Treating Prostate Cancer A Guide for Men With Localized Prostate Cancer Most men have time to learn about all the options for treating their prostate cancer. You have time to talk with your family and
More informationCurrent Clinical Practice. MR Imaging Evaluations. MRI Anatomic Review. Imaging to Address Clinical Challenges. Prostate MR
BETH ISRAEL DEACONESS MEDICAL CENTER Prostate MR Neil M. Rofsky, MD Harvard Medical School Current Clinical Practice DIGITAL RECTAL EXAMINATION PSA ( ~ 20% False negative) BIOPSY (18-25% False negative)
More informationCryotherapy for recurrent prostate cancer. Issue date: May 2005
Issue date: May 2005 Cryotherapy for recurrent Understanding NICE guidance information for people considering the procedure, and for the public Information about NICE Interventional Procedure Guidance
More informationActive Surveillance for Prostate Cancer
PATIENT & CAREGIVER EDUCATION Active Surveillance for Prostate Cancer This information explains a treatment for prostate cancer called active surveillance. Not all prostate cancers are the same. Some may
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationPSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016
PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence
More informationOASIS 1.2T: MULTIPARAMETRIC MRI OF PROSTATE CANCER
OASIS 1.2T: MULTIPARAMETRIC MRI OF PROSTATE CANCER By Dr. John Feller, MD, Radiologist Desert Medical Imaging, Palm Springs, CA MRI is clinically accepted as the best imaging modality for displaying anatomical
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationIndex. B Biologically effective dose (BED), 158
Index B Biologically effective dose (BED), 158 C Catheter displacement, 113, 114 rectal probe, 114 self-anchoring catheters, 113 Catheter fixation, HDR, 106 107 Catheter insertion, HDR sagittal ultrasound
More informationGleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA
Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA Learners Objectives u Latest changes per ISUP 2014 that impact
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More information6th ESUR Teaching Course on Prostate MRI, Berlin 2016
6th ESUR Teaching Course on Prostate MRI, Berlin 2016 Friday, June 10, 2016 8:00 am Registration 8:45 am Welcome Address B. Hamm and H. Thoeny 9:00 10:20 am Session 1 "ABC of the Prostate and mp- MRI:
More informationProstate Cancer Treatment
Scan for mobile link. Prostate Cancer Treatment Prostate cancer overview Prostate cancer is the most common form of cancer in American men, most prevalent in men over age 65 and fairly common in men 50-64
More informationThe Paul Evans Memorial Lecture Functional radiotherapy targeting using focused dose escalation. Roberto Alonzi Mount Vernon Cancer Centre
The Paul Evans Memorial Lecture Functional radiotherapy targeting using focused dose escalation Roberto Alonzi Mount Vernon Cancer Centre Overview Introduction and rationale for focused dose escalation
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationMRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review
MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review Poster No.: C-1208 Congress: ECR 2014 Type: Educational Exhibit Authors: J. Murphy, M.
More information